BR0212008A - Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste - Google Patents
Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação desteInfo
- Publication number
- BR0212008A BR0212008A BR0212008-9A BR0212008A BR0212008A BR 0212008 A BR0212008 A BR 0212008A BR 0212008 A BR0212008 A BR 0212008A BR 0212008 A BR0212008 A BR 0212008A
- Authority
- BR
- Brazil
- Prior art keywords
- solvate
- salt
- compound
- prodrug
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/66—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
"USO DE UM COMPOSTO OU DE UM SAL, SOLVATO OU PRó-MEDICAMENTO DESTE, COMPOSIçãO FARMACêUTICA, COMPOSTO OU UM SAL, SOLVATO OU PRó-MEDICAMENTO DESTE, E, PROCESSO PARA A PREPARAçãO DESTE". A invenção diz respeito ao uso de um composto da Fórmula (I): ou um sal, solvato ou pró-medicamento deste, em que R^ 1^, R^ 2^, R^ 3^, n e m são como descritos no relatório descritivo, na preparação de um medicamento para o tratamento ou prevenção de uma condição de doença mediada através de glicocinase (GLK), tal como diabete tipo 2. A invenção também diz respeito a um novo grupo de compostos da Fórmula (I) e aos métodos de preparar os compostos da Fórmula (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0102764A SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Compounds |
PCT/GB2002/003745 WO2003015774A1 (en) | 2001-08-17 | 2002-08-15 | Compounds effecting glucokinase |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0212008A true BR0212008A (pt) | 2004-09-28 |
Family
ID=20285065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0212008-9A BR0212008A (pt) | 2001-08-17 | 2002-08-15 | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste |
Country Status (32)
Country | Link |
---|---|
US (3) | US7390908B2 (pt) |
EP (12) | EP1529530B3 (pt) |
JP (2) | JP3987829B2 (pt) |
KR (1) | KR100920439B1 (pt) |
CN (4) | CN101584691A (pt) |
AR (1) | AR037898A1 (pt) |
AT (11) | ATE396720T1 (pt) |
AU (1) | AU2002321462B2 (pt) |
BR (1) | BR0212008A (pt) |
CA (1) | CA2457410C (pt) |
CO (1) | CO5560563A2 (pt) |
CY (5) | CY1105746T1 (pt) |
DE (11) | DE60228143D1 (pt) |
DK (5) | DK1661569T3 (pt) |
ES (10) | ES2308609T3 (pt) |
HK (10) | HK1093429A1 (pt) |
HU (1) | HUP0401213A3 (pt) |
IL (2) | IL160219A0 (pt) |
IS (1) | IS7150A (pt) |
MX (1) | MXPA04001500A (pt) |
MY (1) | MY146279A (pt) |
NO (1) | NO20040686L (pt) |
NZ (1) | NZ531193A (pt) |
PL (1) | PL368970A1 (pt) |
PT (5) | PT1661569E (pt) |
RU (1) | RU2329043C9 (pt) |
SE (1) | SE0102764D0 (pt) |
SI (5) | SI1529530T1 (pt) |
TW (1) | TWI333855B (pt) |
UA (1) | UA83182C2 (pt) |
WO (1) | WO2003015774A1 (pt) |
ZA (1) | ZA200401015B (pt) |
Families Citing this family (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0102300D0 (sv) * | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
EP1541564A1 (en) * | 2002-09-10 | 2005-06-15 | Takeda Pharmaceutical Company Limited | Five-membered heterocyclic compounds |
JP2004123732A (ja) * | 2002-09-10 | 2004-04-22 | Takeda Chem Ind Ltd | 5員複素環化合物 |
NZ539013A (en) | 2002-10-03 | 2007-05-31 | Novartis Ag | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
UA82867C2 (en) | 2003-02-13 | 2008-05-26 | Banyu Pharma Co Ltd | 2-pyridinecarboxamide derivatives |
EP1600442B1 (en) | 2003-02-26 | 2018-01-17 | Msd K.K. | Heteroarylcarbamoylbenzene derivative |
JP2006526015A (ja) * | 2003-05-02 | 2006-11-16 | エラン ファーマシューティカルズ,インコーポレイテッド | 炎症疾患治療のためのブラジキニンb1受容体アンタゴニストとしての4−ブロモ−5−(2−クロロ−ベンゾイルアミノ)−1h−ピラゾール−3−カルボン酸アミド誘導体および関連化合物 |
DE602004021933D1 (de) * | 2003-05-02 | 2009-08-20 | Elan Pharm Inc | 4-brom-5-(2-chlor-benzoylamino)-1h-pyrazol-3-carbonsäure(phenyl)amid-derivate und verwandte verbindungen als bradykinin b1 receptor antagonisten zur behandlung von entzündlichen erkrankungen |
MXPA05013733A (es) * | 2003-06-20 | 2006-03-08 | Hoffmann La Roche | 2-aminobenzotiazoles como agonistas inversos del receptor de cb1. |
ES2222822B1 (es) * | 2003-07-28 | 2005-12-16 | Laboratorios Farmaceuticos Rovi, S.A. | Diamidas de aminoacidos en posicion no alfa utiles como adyuvantes para la administracion de agentes biologicos activos. |
JP4667384B2 (ja) | 2003-10-07 | 2011-04-13 | レノビス, インコーポレイテッド | イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法 |
GB0325402D0 (en) * | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
GB0328178D0 (en) * | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
US20080312207A1 (en) * | 2004-02-18 | 2008-12-18 | Craig Johnstone | Compounds |
US20080280872A1 (en) * | 2004-02-18 | 2008-11-13 | Craig Johnstone | Benzamide Derivatives and Their Use as Glucokinase Activating Agents |
CN101098876A (zh) | 2004-04-02 | 2008-01-02 | 诺瓦提斯公司 | 噻唑并吡啶衍生物、包含它们的药物形式以及治疗葡糖激酶介导的病症的方法 |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
WO2005095418A1 (en) | 2004-04-02 | 2005-10-13 | Novartis Ag | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes |
TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
KR100739367B1 (ko) * | 2004-07-14 | 2007-07-16 | 크리스탈지노믹스(주) | 설파마이드 유도체 및 이를 함유하는 지방대사 촉진용약학적 조성물 |
GB0423043D0 (en) * | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
MX2007004560A (es) | 2004-10-16 | 2007-06-08 | Astrazeneca Ab | Proceso para hacer compuestos de fenoxi benzamida. |
GB0423044D0 (en) * | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
US7576099B2 (en) | 2005-02-28 | 2009-08-18 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
CA2609394A1 (en) * | 2005-05-23 | 2006-11-30 | Masaki Takagi | Pyrazole compound and therapeutic agent for diabetes comprising the same |
EP1891069A1 (en) * | 2005-05-24 | 2008-02-27 | AstraZeneca AB | 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators |
GB0510852D0 (en) * | 2005-05-27 | 2005-07-06 | Astrazeneca Ab | Chemical compounds |
TW200714597A (en) * | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
US20080234273A1 (en) * | 2005-07-09 | 2008-09-25 | Mckerrecher Darren | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes |
EP1910350A1 (en) * | 2005-07-09 | 2008-04-16 | AstraZeneca AB | 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes |
GB0514173D0 (en) * | 2005-07-09 | 2005-08-17 | Astrazeneca Ab | Chemical compounds |
BRPI0622261A2 (pt) * | 2005-07-09 | 2011-08-09 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto |
EP1910317B1 (en) | 2005-07-20 | 2013-07-03 | Eli Lilly And Company | 1-amino linked compounds |
US9202182B2 (en) * | 2005-08-11 | 2015-12-01 | International Business Machines Corporation | Method and system for analyzing business architecture |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
CN101272784A (zh) | 2005-09-29 | 2008-09-24 | 塞诺菲-安万特股份有限公司 | 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途 |
GT200600428A (es) | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
AU2006342449B2 (en) | 2005-11-17 | 2012-03-01 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
TW200738621A (en) | 2005-11-28 | 2007-10-16 | Astrazeneca Ab | Chemical process |
JP5302012B2 (ja) | 2006-03-08 | 2013-10-02 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤 |
SI2463283T1 (sl) * | 2006-04-20 | 2014-09-30 | Pfizer Products Inc. | Kondezirane fenil amino heterociklične spojine za preprečevanje in zdravljenje bolezni, ki jih posreduje glukokinaza |
US8211925B2 (en) | 2006-04-28 | 2012-07-03 | Transtech Pharma, Inc. | Benzamide glucokinase activators |
JP2009535318A (ja) | 2006-04-28 | 2009-10-01 | トランステック ファーマ,インコーポレイティド | ベンズアミドグルコキナーゼ活性化剤 |
DE602007010764D1 (en) * | 2006-04-28 | 2011-01-05 | Transtech Pharma Inc | Benzamidglucokinaseaktivatoren |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
UA93548C2 (uk) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
JP5386350B2 (ja) | 2006-05-31 | 2014-01-15 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体 |
US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
US7888504B2 (en) * | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
WO2008012227A2 (en) | 2006-07-24 | 2008-01-31 | F. Hoffmann-La Roche Ag | Pyrazoles as glucokinase activators |
AU2007287070C1 (en) | 2006-08-24 | 2013-02-14 | University Of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
JP5296688B2 (ja) | 2006-09-11 | 2013-09-25 | シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト | 殺虫化合物 |
AR063028A1 (es) | 2006-10-06 | 2008-12-23 | Banyu Pharma Co Ltd | Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen. |
WO2008044700A1 (fr) * | 2006-10-11 | 2008-04-17 | Takeda Pharmaceutical Company Limited | INHIBITEUR DE LA GSK-3β |
TW200825063A (en) * | 2006-10-23 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
SA07280576B1 (ar) | 2006-10-26 | 2011-06-22 | استرازينيكا ايه بي | مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز |
CN101563330B (zh) * | 2006-10-26 | 2012-06-27 | 阿斯利康(瑞典)有限公司 | 作为葡糖激酶(glk)激活剂的苯甲酰氨基杂环化合物 |
TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
EP2096111A1 (en) * | 2006-11-20 | 2009-09-02 | Japan Tobacco Inc. | Pyrazoles and use thereof as drugs |
NZ577109A (en) * | 2006-12-15 | 2011-12-22 | Glaxo Group Ltd | Benzamide derivatives as ep4 receptor agonists |
EP2091947A2 (en) | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinase activators |
US20100094009A1 (en) * | 2006-12-21 | 2010-04-15 | Mccabe James | Novel crystalline compound useful as glk activator |
CA2674237C (en) | 2006-12-28 | 2015-11-24 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
TW200836719A (en) | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
CA2679185A1 (en) * | 2007-02-28 | 2008-09-04 | Advinus Therapeutics Private Limited | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application |
US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CA2688136A1 (en) | 2007-06-08 | 2008-12-11 | Advinus Therapeutics Private Limited | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application |
US8222285B2 (en) | 2007-06-11 | 2012-07-17 | Bristol-Myers Squibb Company | 1,3-dihydroxy substituted phenylamide glucokinase activators |
CA2695517C (en) * | 2007-08-03 | 2016-09-20 | J. Edward Semple | Alkylsulfonyl-substituted thiazolide compounds |
TW200922582A (en) * | 2007-08-20 | 2009-06-01 | Organon Nv | N-benzyl, N'-arylcarbonylpiperazine derivatives |
US8314091B2 (en) | 2007-08-20 | 2012-11-20 | Msd Oss B.V. | N-benzyl,N'-arylcarbonylpiperazine derivatives |
US9340506B2 (en) | 2007-10-08 | 2016-05-17 | Advinus Therapeutics Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
CN101827832B (zh) * | 2007-10-08 | 2014-05-07 | 阿德维纳斯治疗私人有限公司 | 作为葡糖激酶活化剂的乙酰胺衍生物、其制备方法及医药应用 |
EA017114B1 (ru) * | 2007-10-09 | 2012-09-28 | Мерк Патент Гмбх | Производные n-(пиразол-3-ил)бензамида в качестве активаторов глюкокиназы |
AU2008310097B2 (en) * | 2007-10-09 | 2013-05-16 | Merck Patent Gmbh | Pyridine derivatives useful as glucokinase activators |
US8258134B2 (en) | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
CA2722139C (en) | 2008-04-23 | 2017-04-11 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds for the treatment of metabolic disorders |
KR101006311B1 (ko) * | 2008-06-27 | 2011-01-06 | 김정이 | 온수를 이용한 황토 온열매트 및 그 제조방법 |
JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
MX2011001333A (es) | 2008-08-04 | 2011-03-15 | Astrazeneca Ab | Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad. |
CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CN102271509A (zh) | 2008-10-31 | 2011-12-07 | 默沙东公司 | 用于抗糖尿病药的新型环苯并咪唑衍生物 |
WO2010056717A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
JP2012515560A (ja) | 2009-01-26 | 2012-07-12 | ナノインク インコーポレーティッド | 均質基板を含む大面積均質アレイの製作方法 |
US8214916B2 (en) | 2009-01-26 | 2012-07-03 | Nanoink, Inc. | Large area, homogeneous array fabrication including leveling with use of bright spots |
CA2750434A1 (en) | 2009-01-26 | 2010-07-29 | Nanoink, Inc. | Large area, homogeneous array fabrication including substrate temperature control |
GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
WO2010116176A1 (en) * | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity |
WO2010116177A1 (en) | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity |
CN105853415A (zh) | 2009-05-12 | 2016-08-17 | 罗马克实验室有限公司 | 卤代烷基杂芳基苯甲酰胺化合物 |
CA2968113C (en) | 2009-06-26 | 2019-05-14 | Romark Laboratories L.C. | Compounds and methods for treating influenza |
CA2768577A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
JP2013500961A (ja) * | 2009-07-31 | 2013-01-10 | カディラ ヘルスケア リミテッド | グルコキナーゼ(gk)アクチベーターとしての置換ベンズアミド誘導体 |
KR101642097B1 (ko) * | 2009-09-22 | 2016-07-25 | 주식회사유한양행 | 신규의 글루코키나제 활성화제 및 그의 제조방법 |
WO2011035874A1 (de) * | 2009-09-25 | 2011-03-31 | Bayer Cropscience Ag | N-(1,2,5-oxadiazol-3-yl)benzamide und ihre verwendung als herbizide |
US8222416B2 (en) | 2009-12-14 | 2012-07-17 | Hoffmann-La Roche Inc. | Azaindole glucokinase activators |
JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
JP2013522294A (ja) * | 2010-03-18 | 2013-06-13 | タケダ カリフォルニア インコーポレイテッド | 2−アミノ−5−フルオロチアゾールの製造プロセス |
WO2011135355A1 (en) | 2010-04-29 | 2011-11-03 | Astrazeneca Ab | 3-{ [5 -(azetidin-1-ylcarbonyl)pyrazin-2 -yl] oxy} -5-{ [(1s) -2 -hydroxy- 1 -methylethyl]oxy} -n- (5 -methylpyrazin-2-) benzamid monohydrate |
US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
US8697911B2 (en) | 2010-07-07 | 2014-04-15 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
US9079880B2 (en) | 2010-07-07 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
JP5769326B2 (ja) * | 2010-10-19 | 2015-08-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Rhoキナーゼ阻害薬 |
MX2013004724A (es) * | 2010-11-01 | 2013-08-29 | Romark Lab Lc | Compuestos de tiazolida alquilsulfinilo-sustituidos. |
MA34916B1 (fr) | 2011-02-25 | 2014-02-01 | Merck Sharp & Dohme | Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques |
WO2013155600A1 (en) | 2012-04-16 | 2013-10-24 | Kaneq Pharma | Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors |
RU2717835C2 (ru) | 2012-07-13 | 2020-03-26 | Джи Ти Икс, ИНК. | Способ лечения андроген-рецептор(ar)-положительных форм рака молочной железы с использованием селективных модуляторов андрогенных рецепторов (sarm) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
CA2880901A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN102942541B (zh) * | 2012-12-04 | 2014-07-23 | 西北师范大学 | 一种受体化合物及其合成和在比色检测氟离子中的应用 |
RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
EP2970281A4 (en) * | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED BENZENE COMPOUNDS |
US9243001B2 (en) | 2013-03-15 | 2016-01-26 | Epizyme, Inc. | Substituted benzene compounds |
KR102272746B1 (ko) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN104672218A (zh) * | 2015-02-13 | 2015-06-03 | 佛山市赛维斯医药科技有限公司 | 含葡萄糖酰胺结构的葡萄糖激酶活化剂、制备方法及其在治疗2型糖尿病上的用途 |
CN104672219A (zh) * | 2015-02-13 | 2015-06-03 | 佛山市赛维斯医药科技有限公司 | 一类含葡萄糖酰胺结构的葡萄糖激酶活化剂及其用途 |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
WO2018183122A1 (en) * | 2017-03-27 | 2018-10-04 | Sidecar Therapeutics, Inc. | Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds |
GB201714777D0 (en) | 2017-09-14 | 2017-11-01 | Univ London Queen Mary | Agent |
CN110606831A (zh) * | 2018-06-14 | 2019-12-24 | 上海度德医药科技有限公司 | 一种Iclaprim的新中间体及其制备方法和应用 |
CN109879818A (zh) * | 2019-04-04 | 2019-06-14 | 安徽丰乐农化有限责任公司 | N-(4,6-二甲氧基嘧啶-2-基)-4-甲砜基-2-硝基苯甲酰胺的合成方法 |
AU2020304934A1 (en) * | 2019-06-24 | 2022-01-20 | Benevolentai Bio Limited | New compounds and methods |
CN114591192A (zh) * | 2020-12-04 | 2022-06-07 | 江西仰立新材料有限公司 | 一种n-环丙甲基苯胺类化合物的制备方法 |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2750393A (en) * | 1954-12-01 | 1956-06-12 | Sterling Drug Inc | Iodinated 5-henzamidotetrazoles and preparation thereof |
US2967194A (en) * | 1958-05-15 | 1961-01-03 | Pennsalt Chemicals Corp | 4-trifluoromethylsalicylamides |
FR1526074A (fr) | 1967-03-22 | 1968-05-24 | Rech S Ind S O R I Soc D | Méthoxy-phényl-amino-2-thiazoles, leurs amides et leurs procédés de préparation |
GB1352415A (en) | 1970-05-03 | 1974-05-08 | Boots Co Ltd | Esters of substituted nicotine acids |
FR2088019A1 (en) | 1970-05-08 | 1972-01-07 | Rabot Ets David | Esters of 2 and 6-substituted nicotinic acids - with vasomotor active |
CS173097B1 (pt) | 1972-12-01 | 1977-02-28 | ||
GB1400540A (en) * | 1972-12-06 | 1975-07-16 | Smith Kline French Lab | Salicylamides and compositions thereof |
US4009174A (en) * | 1972-12-08 | 1977-02-22 | The Boots Company Limited | Esters of substituted nicotinic acids |
GB1437800A (en) | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
JPS5734314B2 (pt) | 1973-12-22 | 1982-07-22 | ||
GB1561350A (en) * | 1976-11-05 | 1980-02-20 | May & Baker Ltd | Benzamide derivatives |
FR2344284A1 (fr) * | 1976-03-17 | 1977-10-14 | Cerm Cent Europ Rech Mauvernay | Nouveaux composes tricycliques a cycle furannique et leur application comme antidepresseurs |
GB1588242A (en) | 1977-10-28 | 1981-04-23 | May & Baker Ltd | N-(tetrazol-5-yl)-salicylamide derivatives |
US4474792A (en) * | 1979-06-18 | 1984-10-02 | Riker Laboratories, Inc. | N-Tetrazolyl benzamides and anti-allergic use thereof |
JPS5721320A (en) | 1980-07-11 | 1982-02-04 | Chugai Pharmaceut Co Ltd | Blood sugar level depressing agent |
JPS5775962A (en) | 1980-10-29 | 1982-05-12 | Shionogi & Co Ltd | 2-alkoxybenzamide derivative |
FR2493848B2 (fr) | 1980-11-07 | 1986-05-16 | Delalande Sa | Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique |
JPS5869812A (ja) | 1981-10-22 | 1983-04-26 | Chugai Pharmaceut Co Ltd | 血糖降下剤 |
JPS59139357A (ja) * | 1983-01-28 | 1984-08-10 | Torii Yakuhin Kk | アミジン誘導体 |
JPS61205937A (ja) | 1985-03-09 | 1986-09-12 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀カラ−写真感光材料 |
JPS62142168A (ja) | 1985-10-16 | 1987-06-25 | Mitsubishi Chem Ind Ltd | チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤 |
JPS62158252A (ja) * | 1985-12-28 | 1987-07-14 | Kirin Brewery Co Ltd | 4−アミノピリジンベンズアミド誘導体 |
CA1327358C (en) | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
JP2852659B2 (ja) | 1988-03-03 | 1999-02-03 | 富山化学工業株式会社 | ピペラジン誘導体およびその塩 |
DE3822449A1 (de) | 1988-07-02 | 1990-01-04 | Henkel Kgaa | Oxidationshaarfaerbemittel mit neuen kupplern |
JPH03181465A (ja) | 1989-12-11 | 1991-08-07 | Takeda Chem Ind Ltd | キノリン誘導体 |
JPH04300832A (ja) | 1991-03-29 | 1992-10-23 | Tsumura & Co | 2,4−ジアミノ−1,3,5−トリアジン誘導体を有 効成分とするロイコトリエン拮抗剤 |
JPH04300874A (ja) | 1991-03-29 | 1992-10-23 | Tsumura & Co | 新規2,4−ジアミノ−1,3,5−トリアジン誘導体 |
US5258407A (en) | 1991-12-31 | 1993-11-02 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
US5466715A (en) | 1991-12-31 | 1995-11-14 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
US5273986A (en) * | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
JPH0627025A (ja) | 1992-07-06 | 1994-02-04 | Toto Ltd | 分子認識機能膜及びこれを用いたセンサー |
EP0619116A3 (en) | 1993-04-05 | 1994-11-23 | Hoechst Japan | Use of synthetic retinoids for osteopathy. |
GB9307527D0 (en) | 1993-04-13 | 1993-06-02 | Fujisawa Pharmaceutical Co | New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
JP3869462B2 (ja) | 1993-08-24 | 2007-01-17 | メディヴィル・アクチボラグ | Hivおよび関連ウイルスを阻害するための化合物および方法 |
ES2164153T3 (es) | 1994-06-21 | 2002-02-16 | Otsuka Pharma Co Ltd | Derivado de pirazolo(1,5-a)pirimidina. |
US5661153A (en) | 1994-07-19 | 1997-08-26 | Japan Energy Corporation | 1-arylpyrimidine derivatives and pharmaceutical use thereof |
US5792109A (en) * | 1994-09-01 | 1998-08-11 | Leland L. Ladd | Irrigation pump and system |
GB9420557D0 (en) | 1994-10-12 | 1994-11-30 | Zeneca Ltd | Aromatic compounds |
JPH08143565A (ja) | 1994-11-16 | 1996-06-04 | Fujisawa Pharmaceut Co Ltd | ベンズアミド化合物 |
US5510478A (en) * | 1994-11-30 | 1996-04-23 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
US5672750A (en) * | 1994-12-16 | 1997-09-30 | Eastman Chemical Company | Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride |
KR100432843B1 (ko) | 1994-12-20 | 2004-10-14 | 에프. 호프만-라 로슈 아게 | 아릴-및헤트아릴-설폰아미드유도체,이들의제조방법및이들의엔도텔린길항제로서의용도 |
US5700796A (en) | 1995-01-17 | 1997-12-23 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5753648A (en) | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5849735A (en) * | 1995-01-17 | 1998-12-15 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5696112A (en) | 1995-01-17 | 1997-12-09 | American Cyanamid Company | Fused heterocyclic azepines as vasopressin antagonists |
AR002459A1 (es) | 1995-01-17 | 1998-03-25 | American Cyanamid Co | Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion. |
US5532235A (en) | 1995-01-17 | 1996-07-02 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5536718A (en) | 1995-01-17 | 1996-07-16 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
JPH08301760A (ja) | 1995-05-10 | 1996-11-19 | Shiseido Co Ltd | 皮膚外用剤 |
PT870765E (pt) | 1995-05-18 | 2004-03-31 | Zeria Pharm Co Ltd | Derivados de aminotiazole drogas contendo os mesmos e intermediarios na producao dos compostos |
JP3168915B2 (ja) | 1995-05-25 | 2001-05-21 | 田辺製薬株式会社 | 医薬組成物 |
GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
US5712270A (en) * | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
JP3735741B2 (ja) | 1995-11-24 | 2006-01-18 | 株式会社大塚製薬工場 | 縮環ピリミジン誘導体 |
JP3870298B2 (ja) | 1996-06-06 | 2007-01-17 | 株式会社大塚製薬工場 | アミド誘導体 |
JPH10101672A (ja) | 1996-08-06 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | アデノシン増強剤 |
JPH10101671A (ja) | 1996-08-08 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | 一酸化窒素合成酵素阻害剤 |
AUPO395396A0 (en) * | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
FR2757852B1 (fr) * | 1996-12-31 | 1999-02-19 | Cird Galderma | Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations |
JPH10212271A (ja) | 1997-01-31 | 1998-08-11 | Zeria Pharmaceut Co Ltd | N−置換ベンゾイルアミン誘導体、それを含有する医薬及び該化合物の製造中間体 |
JPH1129480A (ja) | 1997-05-12 | 1999-02-02 | Otsuka Pharmaceut Factory Inc | 縮環ピリミジン誘導体を含有する医薬組成物 |
BR9810456A (pt) * | 1997-06-27 | 2001-09-25 | Fujisawa Pharmaceutical Co | Composto de sulfonamida, método para sua obtenção e seu uso farmacêutico |
US6242474B1 (en) * | 1997-06-27 | 2001-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Aromatic ring derivatives |
US6613942B1 (en) * | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
US6114483A (en) | 1997-08-27 | 2000-09-05 | E. I. Du Pont De Nemours And Company | Polymerization of olefins |
EP1048659A4 (en) | 1997-11-12 | 2002-11-20 | Inst Med Molecular Design Inc | RETINOID RECEPTOR AGONISTS |
GB9725298D0 (en) | 1997-11-28 | 1998-01-28 | Zeneca Ltd | Insecticidal thiazole derivatives |
JP3811006B2 (ja) | 1997-12-19 | 2006-08-16 | シエーリング アクチエンゲゼルシャフト | 抗凝血物質類としてのオルト−アントラニルアミド誘導体類 |
JP4253126B2 (ja) * | 1998-01-29 | 2009-04-08 | アムジェン インコーポレイテッド | Ppar−ガンマ調節剤 |
JP3937367B2 (ja) | 1998-02-05 | 2007-06-27 | 株式会社大塚製薬工場 | 一酸化窒素合成酵素阻害剤 |
JPH11292879A (ja) * | 1998-04-08 | 1999-10-26 | Otsuka Pharmaceut Factory Inc | カルボキサミド誘導体 |
DE19816780A1 (de) * | 1998-04-16 | 1999-10-21 | Bayer Ag | Substituierte 2-Oxo-alkansäure-[2-(indol-3-yl)-ethyl]amide |
GB9811969D0 (en) * | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
US6197798B1 (en) | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
JP4191825B2 (ja) | 1998-09-10 | 2008-12-03 | あすか製薬株式会社 | 5−アミノイソキサゾール誘導体 |
GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
EP1140903B1 (en) * | 1998-12-23 | 2004-08-04 | Eli Lilly And Company | Aromatic amides |
US6320050B1 (en) * | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
RU2242469C2 (ru) * | 1999-03-29 | 2004-12-20 | Ф.Хоффманн-Ля Рош Аг | Активаторы глюкокиназы |
US6610846B1 (en) * | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
HUP0200396A3 (en) * | 1999-03-29 | 2003-04-28 | Hoffmann La Roche | Gluckokinase activators, process for their preparation, pharmaceutical compositions containing them and their use |
JP2003531103A (ja) | 1999-08-12 | 2003-10-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | c−JUNN−末端キナーゼ(JNK)および他のタンパク質キナーゼの阻害剤 |
GB9921684D0 (en) | 1999-09-15 | 1999-11-17 | Zeneca Ltd | Assays |
DE60040676D1 (de) * | 1999-09-17 | 2008-12-11 | Millennium Pharm Inc | BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa |
AU1917201A (en) * | 1999-11-18 | 2001-05-30 | Centaur Pharmaceuticals, Inc. | Amide therapeutics and methods for treating inflammatory bowel disease |
US6353111B1 (en) * | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
EP1259485B1 (en) | 2000-02-29 | 2005-11-30 | Millennium Pharmaceuticals, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
EP1132381A1 (en) | 2000-03-08 | 2001-09-12 | Cermol S.A. | Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them |
AU776053B2 (en) | 2000-03-31 | 2004-08-26 | Astellas Pharma Inc. | Diazepan derivatives or salts thereof |
US6534651B2 (en) * | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
ATE286036T1 (de) * | 2000-05-03 | 2005-01-15 | Hoffmann La Roche | Heteroaromatische alkynylphenyl-verbindungen als glukokinase-aktivatoren |
JP3842131B2 (ja) | 2000-05-03 | 2006-11-08 | エフ.ホフマン−ラ ロシュ アーゲー | ヒダントイン含有グルコキナーゼ活性化物質 |
ES2230309T3 (es) | 2000-05-08 | 2005-05-01 | F. Hoffmann-La Roche Ag | Fenilacetamidas sustituidas y su empleo con ativadores de qucokinasa. |
ES2307623T3 (es) | 2000-05-08 | 2008-12-01 | F. Hoffmann-La Roche Ag | Activadores de fenilamida glucokinasa para-amina sustituida. |
AU2001287600B2 (en) | 2000-07-20 | 2006-07-13 | F. Hoffmann-La Roche Ag | Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
US6369232B1 (en) | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
DE60118225T2 (de) | 2000-09-25 | 2007-05-03 | Janssen Pharmaceutica N.V. | Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren |
WO2002026718A2 (en) | 2000-09-29 | 2002-04-04 | Millennium Pharmaceutical, Inc. | Bicyclic pyrimidin-4-one based inhibitors of factor xa |
AU2002211281A1 (en) | 2000-09-29 | 2002-04-08 | Millenium Pharmaceuticals, Inc. | Quaternary amidino based inhibitors of factor xa |
EP1336605B1 (en) | 2000-11-22 | 2006-04-12 | Astellas Pharma Inc. | Substituted phenol derivatives or salts thereof as inhibitors of coagulation factor x |
WO2002046173A1 (en) * | 2000-12-06 | 2002-06-13 | F. Hoffmann-La Roche Ag | Fused heteroaromatic glucokinase activators |
US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
CN1289072C (zh) * | 2000-12-22 | 2006-12-13 | 石原产业株式会社 | 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂 |
US20040077697A1 (en) * | 2001-02-02 | 2004-04-22 | Hiroyuki Koshio | 2-Acylaminothiazole derivative or its salt |
DE60221505D1 (de) | 2001-03-30 | 2007-09-13 | Millennium Pharm Inc | FAKTOR Xa BENZAMIDIN INHIBITOREN |
SE0102300D0 (sv) * | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
PL368129A1 (en) * | 2001-08-09 | 2005-03-21 | Ono Pharmaceutical Co, Ltd. | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
TWI325302B (en) | 2001-08-13 | 2010-06-01 | Du Pont | Benzoxazinone compounds |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
TWI283164B (en) | 2001-09-21 | 2007-07-01 | Du Pont | Anthranilamide arthropodicide treatment |
CN104744461A (zh) | 2001-09-21 | 2015-07-01 | 百时美施贵宝公司 | 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂 |
EP1453541A1 (en) | 2001-12-03 | 2004-09-08 | Novo Nordisk A/S | Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
EP1336607A1 (en) | 2002-02-19 | 2003-08-20 | Novo Nordisk A/S | Amide derivatives as glucokinase activators |
US6911545B2 (en) | 2001-12-19 | 2005-06-28 | Hoffman-La Roche Inc. | Crystals of glucokinase and methods of growing them |
AU2002351748B2 (en) | 2001-12-21 | 2009-07-09 | Novo Nordisk A/S | Amide derivatives as GK activators |
CA2488161A1 (en) | 2002-03-26 | 2003-10-02 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
CN100357283C (zh) | 2002-04-02 | 2007-12-26 | 中国科学院上海药物研究所 | 一类甲硫氨酰氨肽酶抑制剂 |
PL373701A1 (en) | 2002-04-26 | 2005-09-05 | F.Hoffmann-La Roche Ag | Substituted phenylacetamides and their use as glucokinase activators |
US20070231874A1 (en) | 2002-05-16 | 2007-10-04 | Kenji Kamata | Crystal of glucokinase protein, and method for drug design using the crystal |
KR101116627B1 (ko) | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
US20060004010A1 (en) * | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
CA2499329C (en) | 2002-10-03 | 2009-04-21 | F. Hoffmann-La Roche Ag | Indole-3-carboxamides as glucokinase (gk) activators |
GB0226931D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
EP1600442B1 (en) * | 2003-02-26 | 2018-01-17 | Msd K.K. | Heteroarylcarbamoylbenzene derivative |
GB0325402D0 (en) * | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
US20050197371A1 (en) * | 2003-11-13 | 2005-09-08 | Ambit Biosciences Corporation | Urea derivatives as PDGFR modulators |
JP4707560B2 (ja) | 2003-12-29 | 2011-06-22 | Msd株式会社 | 新規2−ヘテロアリール置換ベンズイミダゾール誘導体 |
ATE524467T1 (de) | 2005-04-25 | 2011-09-15 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
-
2001
- 2001-08-17 SE SE0102764A patent/SE0102764D0/xx unknown
-
2002
- 2002-08-15 AT AT06001808T patent/ATE396720T1/de active
- 2002-08-15 DK DK06001807T patent/DK1661569T3/da active
- 2002-08-15 AT AT04028297T patent/ATE359781T1/de active
- 2002-08-15 KR KR1020047002287A patent/KR100920439B1/ko not_active IP Right Cessation
- 2002-08-15 DE DE60228143T patent/DE60228143D1/de not_active Expired - Lifetime
- 2002-08-15 EP EP04028298A patent/EP1529530B3/en not_active Expired - Lifetime
- 2002-08-15 HU HU0401213A patent/HUP0401213A3/hu unknown
- 2002-08-15 AT AT06001807T patent/ATE397927T1/de active
- 2002-08-15 DE DE60213678T patent/DE60213678T3/de not_active Expired - Lifetime
- 2002-08-15 EP EP06009486A patent/EP1695705B1/en not_active Expired - Lifetime
- 2002-08-15 EP EP06001809A patent/EP1669068B1/en not_active Expired - Lifetime
- 2002-08-15 CA CA2457410A patent/CA2457410C/en not_active Expired - Fee Related
- 2002-08-15 EP EP02755165A patent/EP1420784B1/en not_active Expired - Lifetime
- 2002-08-15 WO PCT/GB2002/003745 patent/WO2003015774A1/en active Application Filing
- 2002-08-15 DE DE60226914T patent/DE60226914D1/de not_active Expired - Lifetime
- 2002-08-15 DK DK04028298T patent/DK1529530T5/da active
- 2002-08-15 PT PT06001807T patent/PT1661569E/pt unknown
- 2002-08-15 EP EP06001796A patent/EP1674097B1/en not_active Expired - Lifetime
- 2002-08-15 ES ES06001809T patent/ES2308609T3/es not_active Expired - Lifetime
- 2002-08-15 AT AT06001806T patent/ATE406891T1/de not_active IP Right Cessation
- 2002-08-15 AT AT04028298T patent/ATE334678T1/de active
- 2002-08-15 DE DE60228770T patent/DE60228770D1/de not_active Expired - Lifetime
- 2002-08-15 DK DK06001808T patent/DK1661563T3/da active
- 2002-08-15 DE DE60227121T patent/DE60227121D1/de not_active Expired - Lifetime
- 2002-08-15 ES ES04028297T patent/ES2285341T7/es active Active
- 2002-08-15 UA UA2004020927A patent/UA83182C2/ru unknown
- 2002-08-15 DE DE60228897T patent/DE60228897D1/de not_active Expired - Lifetime
- 2002-08-15 DE DE60227120T patent/DE60227120D1/de not_active Expired - Lifetime
- 2002-08-15 IL IL16021902A patent/IL160219A0/xx not_active IP Right Cessation
- 2002-08-15 MX MXPA04001500A patent/MXPA04001500A/es active IP Right Grant
- 2002-08-15 PT PT06001808T patent/PT1661563E/pt unknown
- 2002-08-15 AT AT02755165T patent/ATE323487T1/de not_active IP Right Cessation
- 2002-08-15 ES ES06001796T patent/ES2307237T3/es not_active Expired - Lifetime
- 2002-08-15 ES ES06001808T patent/ES2306300T3/es not_active Expired - Lifetime
- 2002-08-15 ES ES06001806T patent/ES2312050T3/es not_active Expired - Lifetime
- 2002-08-15 AT AT06001810T patent/ATE407672T1/de not_active IP Right Cessation
- 2002-08-15 RU RU2004104333/15A patent/RU2329043C9/ru not_active IP Right Cessation
- 2002-08-15 PT PT06001809T patent/PT1669068E/pt unknown
- 2002-08-15 EP EP06001808A patent/EP1661563B1/en not_active Expired - Lifetime
- 2002-08-15 SI SI200230410T patent/SI1529530T1/sl unknown
- 2002-08-15 SI SI200230559T patent/SI1568367T1/sl unknown
- 2002-08-15 US US10/486,496 patent/US7390908B2/en not_active Expired - Fee Related
- 2002-08-15 ES ES04028298T patent/ES2270263T7/es active Active
- 2002-08-15 SI SI200230710T patent/SI1661569T1/sl unknown
- 2002-08-15 AT AT06001809T patent/ATE397928T1/de active
- 2002-08-15 AT AT06009486T patent/ATE403427T1/de not_active IP Right Cessation
- 2002-08-15 AT AT06001796T patent/ATE397929T1/de not_active IP Right Cessation
- 2002-08-15 ES ES06009486T patent/ES2309862T3/es not_active Expired - Lifetime
- 2002-08-15 EP EP06001807A patent/EP1661569B1/en not_active Expired - Lifetime
- 2002-08-15 NZ NZ531193A patent/NZ531193A/en not_active IP Right Cessation
- 2002-08-15 PL PL02368970A patent/PL368970A1/xx not_active Application Discontinuation
- 2002-08-15 BR BR0212008-9A patent/BR0212008A/pt not_active IP Right Cessation
- 2002-08-15 DK DK04028297T patent/DK1568367T5/da active
- 2002-08-15 DK DK06001809T patent/DK1669068T3/da active
- 2002-08-15 SI SI200230709T patent/SI1669068T1/sl unknown
- 2002-08-15 PT PT04028298T patent/PT1529530E/pt unknown
- 2002-08-15 AT AT06001805T patent/ATE397926T1/de not_active IP Right Cessation
- 2002-08-15 ES ES06001810T patent/ES2312051T3/es not_active Expired - Lifetime
- 2002-08-15 ES ES06001807T patent/ES2307239T3/es not_active Expired - Lifetime
- 2002-08-15 JP JP2003520733A patent/JP3987829B2/ja not_active Expired - Fee Related
- 2002-08-15 DE DE60219698T patent/DE60219698T3/de not_active Expired - Lifetime
- 2002-08-15 EP EP06001806A patent/EP1661568B1/en not_active Expired - Lifetime
- 2002-08-15 CN CNA2009101454369A patent/CN101584691A/zh active Pending
- 2002-08-15 EP EP06001810A patent/EP1669069B1/en not_active Expired - Lifetime
- 2002-08-15 ES ES06001805T patent/ES2307238T3/es not_active Expired - Lifetime
- 2002-08-15 DE DE60227122T patent/DE60227122D1/de not_active Expired - Lifetime
- 2002-08-15 EP EP06001805A patent/EP1661567B1/en not_active Expired - Lifetime
- 2002-08-15 EP EP04028297A patent/EP1568367B3/en not_active Expired - Lifetime
- 2002-08-15 SI SI200230703T patent/SI1661563T1/sl unknown
- 2002-08-15 PT PT04028297T patent/PT1568367E/pt unknown
- 2002-08-15 CN CN200910224498A patent/CN101704797A/zh active Pending
- 2002-08-15 DE DE60210782T patent/DE60210782T2/de not_active Expired - Lifetime
- 2002-08-15 EP EP08161275A patent/EP1987831A1/en not_active Withdrawn
- 2002-08-15 DE DE60227119T patent/DE60227119D1/de not_active Expired - Lifetime
- 2002-08-15 AU AU2002321462A patent/AU2002321462B2/en not_active Ceased
- 2002-08-15 CN CN2008101903170A patent/CN101492416B/zh not_active Expired - Fee Related
- 2002-08-15 CN CN02820347A patent/CN100577163C/zh not_active Expired - Fee Related
- 2002-08-16 AR ARP020103107A patent/AR037898A1/es unknown
- 2002-08-16 TW TW097137990A patent/TWI333855B/zh not_active IP Right Cessation
-
2004
- 2004-02-06 ZA ZA200401015A patent/ZA200401015B/xx unknown
- 2004-02-13 IS IS7150A patent/IS7150A/is unknown
- 2004-02-17 NO NO20040686A patent/NO20040686L/no not_active Application Discontinuation
- 2004-03-10 CO CO04022003A patent/CO5560563A2/es not_active Application Discontinuation
- 2004-09-28 HK HK06113586.7A patent/HK1093429A1/xx not_active IP Right Cessation
- 2004-09-28 HK HK05111879A patent/HK1079692A1/xx not_active IP Right Cessation
- 2004-09-28 HK HK04107483A patent/HK1064598A1/xx not_active IP Right Cessation
- 2004-09-28 HK HK06110634.5A patent/HK1089958A1/xx not_active IP Right Cessation
- 2004-09-28 HK HK05108225A patent/HK1076042A1/xx not_active IP Right Cessation
-
2005
- 2005-06-09 JP JP2005168987A patent/JP4441446B2/ja not_active Expired - Fee Related
-
2006
- 2006-09-25 HK HK06110673A patent/HK1089960A1/xx not_active IP Right Cessation
- 2006-09-27 HK HK06110762.9A patent/HK1089966A1/xx not_active IP Right Cessation
- 2006-10-04 HK HK06110988A patent/HK1090291A1/xx not_active IP Right Cessation
- 2006-10-05 HK HK06111020.5A patent/HK1090292A1/xx not_active IP Right Cessation
- 2006-10-18 HK HK06111482.6A patent/HK1090839A1/xx not_active IP Right Cessation
- 2006-11-01 CY CY20061101565T patent/CY1105746T1/el unknown
-
2007
- 2007-06-22 CY CY20071100836T patent/CY1107683T1/el unknown
-
2008
- 2008-02-01 US US12/024,561 patent/US7524957B2/en not_active Expired - Fee Related
- 2008-08-12 CY CY20081100851T patent/CY1108254T1/el unknown
- 2008-08-18 CY CY20081100873T patent/CY1108267T1/el unknown
- 2008-08-21 CY CY20081100889T patent/CY1108276T1/el unknown
-
2009
- 2009-02-02 US US12/363,899 patent/US7951830B2/en not_active Expired - Fee Related
-
2010
- 2010-02-11 IL IL203923A patent/IL203923A/en not_active IP Right Cessation
- 2010-11-09 MY MYPI2010005251A patent/MY146279A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
BR0210711A (pt) | Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto | |
BRPI0416283A (pt) | compostos, processo para a fabricação de compostos, composição farmacêutica, método para o tratamento e/ou prevenção de doenças que são moduladas por agonistas de ppar(delta) e/ou ppar(alfa) e uso destes compostos | |
BR0213539A (pt) | Compostos, processo para a preparação de compostos, composições farmacêuticas que compreendem um composto método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp iv e utilização desses compostos | |
BR0317268A (pt) | Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos | |
BR0112224A (pt) | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto | |
BR9907270A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto | |
BR0313266A (pt) | Compostos, respectivos processos de preparação e uso, formulação farmacêutica e métodos de prevenção e/ou tratamento de um distúrbio mediado pelo receptor de mglur5 e de inibição da ativação de receptores de mglur5 | |
BRPI0512796A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf, e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença | |
BRPI0512075A (pt) | composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença | |
BR0010555A (pt) | Inibidores de neuraminidases | |
BRPI0410760A (pt) | compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos | |
BR0113989A (pt) | Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos | |
BR0009864A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto | |
BR0210008A (pt) | Derivados de feniluréia substituìdos com carboxamida, processos para produção dos mesmos como medicamentos | |
BRPI0312398B8 (pt) | derivado de 1,3-difenilprop-2-en-1-ona substituído, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituído | |
BR0214986A (pt) | S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica | |
BR0309167A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação | |
BRPI0612104A8 (pt) | composto, mistura diastereomérica, composição farmacêutica, e, método para tratar infecções por hepatite c em um paciente e para tratar infecções por hcv em um paciente | |
BR0314379A (pt) | Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase | |
BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
BRPI0614168A2 (pt) | Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto | |
BRPI0514679A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença ou condição | |
BRPI0418004A (pt) | composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis, métodos para tratar ou prevenir condições hiperlipidêmicas, aterosclerose, mal de alzheimer, e tumores associados com colesterol, formulação farmacêutica, combinação, e, processo para preparar um composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis | |
BR9910573A (pt) | Compostos antipicornavirais, preparação e uso dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014. |